9th Aug 2022 17:11
Fusion Antibodies PLC - Belfast-based antibody developer - Submits patent application for its bispecific designs for antigen display. The designs include an antigen part, and a "reporter" part, called a "bispecific". Believes the reporter part will increase the rate of success in the identification of highly potent antibodies from its range of Antibody Discovery technologies.
"Our dedicated team of scientists continues to work on next generation antibody discovery, and we see significant opportunities in this field. We look forward to contributing to the growing body of research concerning the scope of antibody production and design, while also growing our patent portfolio," says Chair Simon Douglas.
Current stock price: 96.00 pence, up 9.7% on Tuesday in London
12-month change: down 29%
By Elizabeth Winter; [email protected]
Copyright 2022 Alliance News Limited. All Rights Reserved.
Related Shares:
Fusion Antibodies